|
07 Sep 2025 |
Dr. Reddy's Labs
|
Consensus Share Price Target
|
1268.10 |
1287.37 |
- |
1.52 |
hold
|
|
|
|
|
31 Jan 2024
|
Dr. Reddy's Labs
|
Axis Direct
|
1268.10
|
6000.00
|
6121.15
(-79.28%)
|
Target met |
Hold
|
|
|
We believe the company's strategy of investing in various businesses may provide growth in the long term. Recommendation: HOLD
|
|
31 Jan 2024
|
Dr. Reddy's Labs
|
SMC online
|
1268.10
|
|
6121.15
(-79.28%)
|
Pre-Bonus/ Split |
Results Update
|
|
|
|
|
31 Jan 2024
|
Dr. Reddy's Labs
|
Motilal Oswal
|
1268.10
|
5540.00
|
6121.15
(-79.28%)
|
Pre-Bonus/ Split |
Neutral
|
|
|
|
|
31 Jan 2024
|
Dr. Reddy's Labs
|
BOB Capital Markets Ltd.
|
1268.10
|
5900.00
|
6121.15
(-79.28%)
|
Target met |
Hold
|
|
|
Healthy quarter with revenue/PAT coming in 3%/4% ahead of consensus; US sales a positive surprise, rising 6% QoQ
|
|
30 Oct 2023
|
Dr. Reddy's Labs
|
SMC online
|
1268.10
|
|
5345.35
(-76.28%)
|
Pre-Bonus/ Split |
Results Update
|
|
|
|
|
30 Oct 2023
|
Dr. Reddy's Labs
|
Axis Direct
|
1268.10
|
5850.00
|
5345.35
(-76.28%)
|
Target met |
Hold
|
|
|
We believe the company's strategy of investing in various businesses may provide growth in the long term
|
|
30 Oct 2023
|
Dr. Reddy's Labs
|
BOB Capital Markets Ltd.
|
1268.10
|
5500.00
|
5345.35
(-76.28%)
|
Target met |
Hold
|
|
|
Q2 revenue in line but PAT outdid consensus by 22% on account of PLI benefits, litigation settlement and interest income
|
|
29 Oct 2023
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1268.10
|
5300.00
|
5397.30
(-76.50%)
|
Target met |
Sell
|
|
|
|
|
28 Oct 2023
|
Dr. Reddy's Labs
|
ICICI Securities Limited
|
1268.10
|
6000.00
|
5397.30
(-76.50%)
|
Target met |
Accumulate
|
|
|
Dr. Reddy’s Laboratories’ (DRL) Q2FY24 gross and EBITDA margins were down 198bps/273bps YoY to 58.7%/28.9%, respectively. US price erosion, acquisition of Mayne Pharma and higher SG&A investments dented margins.
|
|
28 Oct 2023
|
Dr. Reddy's Labs
|
Motilal Oswal
|
1268.10
|
5400.00
|
5397.30
(-76.50%)
|
Target met |
Neutral
|
|
|
|